Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

Covid-19

 

Scientists working in a lab vector concept illustration. Biochemistry experiments, Vaccine and drug treatment development, clinical research vector illustration for web and app
Scientists working in a lab vector concept illustration. Biochemistry experiments, Vaccine and drug treatment development, clinical research vector illustration for web and app
article

2023 and beyond: revolutionising drug discovery

26 January 2023 | By

Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…

Medical technology concept. Remote medicine. Electronic medical record.
Medical technology concept. Remote medicine. Electronic medical record.
article

Artificial intelligence-aided screening could boost speed of new drug discovery

15 December 2022 | By ,

Using a natural language-inspired technique, researchers at the University of Central Florida, US, developed an interpretable and generalisable drug target interaction model that achieves 97 percent accuracy in identifying drug candidates for a broad variety of target proteins. Here, Dr Ozlem Ozmen Garibay and Aida Tayebi, who worked on the…

in silico
in silico
article

Rapidly transitioning from in silico hits to leads on ‘undruggable’ pain targets

13 December 2022 | By ,

Opioid addiction is an ongoing crisis in the US. Researchers have identified a key regulator that shapes analgesic and aversive outputs of kappa opioid receptor signalling, finding lead inhibitors of this previously ‘undruggable’ target class – the Regulators of G protein Signalling (RGS proteins) – to help re-establish non-addictive kappa…